Serum heme oxygenase-1 measurement is useful for evaluating disease activity and outcomes in patients with acute respiratory distress syndrome and acute exacerbation of interstitial lung disease.
Acute respiratory distress syndrome
Disease activity
Heme oxygenase-1
Interstitial lung disease
Lung injury
Outcome
Oxidative stress
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
25 Nov 2020
25 Nov 2020
Historique:
received:
02
07
2020
accepted:
09
11
2020
entrez:
26
11
2020
pubmed:
27
11
2020
medline:
10
8
2021
Statut:
epublish
Résumé
Oxidative stress plays an important role in acute lung injury, which is associated with the development and progression of acute respiratory failure. Here, we investigated whether the degree of oxidative stress as indicated by serum heme oxygenase-1 (HO-1) is clinically useful for predicting prognosis among the patients with acute respiratory distress syndrome (ARDS) and acute exacerbation of interstitial lung disease (AE-ILD). Serum HO-1 levels of newly diagnosed or untreated ARDS and AE-ILD patients were measured at diagnosis. Relationships between serum HO-1 and other clinical parameters and 1 and 3-month mortality were evaluated. Fifty-five patients including 22 of ARDS and 33 of AE-ILD were assessed. Serum HO-1 level at diagnosis was significantly higher in ARDS patients than AE-ILD patients (87.8 ± 60.0 ng/mL vs. 52.5 ± 36.3 ng/mL, P < 0.001). Serum HO-1 correlated with serum total bilirubin (R = 0.454, P < 0.001) and serum LDH (R = 0.500, P < 0.001). In both patients with ARDS and AE-ILDs, serum HO-1 level tended to decrease from diagnosis to 2 weeks after diagnosis, however, did not normalized. Composite parameters including serum HO-1, age, sex, and partial pressure of oxygen in arterial blood/fraction of inspired oxygen (P/F) ratio for prediction of 3-month mortality showed a higher AUC (ARDS: 0.925, AE-ILDs: 0.892) than did AUCs of a single predictor or combination of two or three predictors. Oxidative stress assessed by serum HO-1 is persistently high among enrolled patients for 2 weeks after diagnosis. Also, serum HO-1 levels at the diagnosis combined with age, sex, and P/F ratio could be clinically useful for predicting 3-month mortality in both ARDS and AE-ILD patients.
Sections du résumé
BACKGROUND
BACKGROUND
Oxidative stress plays an important role in acute lung injury, which is associated with the development and progression of acute respiratory failure. Here, we investigated whether the degree of oxidative stress as indicated by serum heme oxygenase-1 (HO-1) is clinically useful for predicting prognosis among the patients with acute respiratory distress syndrome (ARDS) and acute exacerbation of interstitial lung disease (AE-ILD).
METHODS
METHODS
Serum HO-1 levels of newly diagnosed or untreated ARDS and AE-ILD patients were measured at diagnosis. Relationships between serum HO-1 and other clinical parameters and 1 and 3-month mortality were evaluated.
RESULTS
RESULTS
Fifty-five patients including 22 of ARDS and 33 of AE-ILD were assessed. Serum HO-1 level at diagnosis was significantly higher in ARDS patients than AE-ILD patients (87.8 ± 60.0 ng/mL vs. 52.5 ± 36.3 ng/mL, P < 0.001). Serum HO-1 correlated with serum total bilirubin (R = 0.454, P < 0.001) and serum LDH (R = 0.500, P < 0.001). In both patients with ARDS and AE-ILDs, serum HO-1 level tended to decrease from diagnosis to 2 weeks after diagnosis, however, did not normalized. Composite parameters including serum HO-1, age, sex, and partial pressure of oxygen in arterial blood/fraction of inspired oxygen (P/F) ratio for prediction of 3-month mortality showed a higher AUC (ARDS: 0.925, AE-ILDs: 0.892) than did AUCs of a single predictor or combination of two or three predictors.
CONCLUSION
CONCLUSIONS
Oxidative stress assessed by serum HO-1 is persistently high among enrolled patients for 2 weeks after diagnosis. Also, serum HO-1 levels at the diagnosis combined with age, sex, and P/F ratio could be clinically useful for predicting 3-month mortality in both ARDS and AE-ILD patients.
Identifiants
pubmed: 33238962
doi: 10.1186/s12890-020-01341-1
pii: 10.1186/s12890-020-01341-1
pmc: PMC7687749
doi:
Substances chimiques
Heme Oxygenase-1
EC 1.14.14.18
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
310Références
Proc Biol Sci. 2019 Nov 20;286(1915):20191698
pubmed: 31718494
Am J Respir Cell Mol Biol. 2007 Feb;36(2):166-74
pubmed: 16990612
Expert Opin Ther Targets. 2018 Dec;22(12):1049-1061
pubmed: 30445883
Hum Pathol. 2001 Nov;32(11):1257-63
pubmed: 11727267
Eur Respir J. 1999 Jan;13(1):169-74
pubmed: 10836343
Am J Respir Crit Care Med. 2005 Aug 15;172(4):417-22
pubmed: 15894605
Biochem Biophys Res Commun. 2005 Dec 9;338(1):558-67
pubmed: 16115609
Crit Care Med. 1985 Oct;13(10):818-29
pubmed: 3928249
Am J Respir Cell Mol Biol. 2008 Dec;39(6):673-82
pubmed: 18566336
Inflammation. 2020 Feb;43(1):1-7
pubmed: 31297749
Nitric Oxide. 2019 Aug 1;89:41-45
pubmed: 31054949
Crit Care Med. 2004 May;32(5):1130-5
pubmed: 15190962
Chest. 2007 Jul;132(1):214-20
pubmed: 17400667
Can Respir J. 2018 Apr 18;2018:9627420
pubmed: 29849835
Respir Res. 2018 Aug 1;19(1):144
pubmed: 30068325
J Thorac Dis. 2015 Mar;7(3):499-519
pubmed: 25922733
Front Cell Infect Microbiol. 2018 May 16;8:161
pubmed: 29868517
Eur Respir J. 2011 Feb;37(2):356-63
pubmed: 20595144
Chest. 2007 Nov;132(5):1652-8
pubmed: 17998366
Chest. 2005 Oct;128(4):2387-92
pubmed: 16236899
Am J Surg Pathol. 2007 Feb;31(2):277-84
pubmed: 17255773
Crit Care. 2006;10(6):R154
pubmed: 17083735
Crit Care. 2015 May 15;19:228
pubmed: 25981598
N Engl J Med. 2005 Oct 20;353(16):1711-23
pubmed: 16236742
Am J Physiol Lung Cell Mol Physiol. 2018 Apr 1;314(4):L642-L653
pubmed: 29351446
Am J Physiol Lung Cell Mol Physiol. 2019 Feb 1;316(2):L369-L384
pubmed: 30520687
Respir Med. 2009 Sep;103(9):1245-56
pubmed: 19464864
Am J Respir Cell Mol Biol. 2007 Feb;36(2):158-65
pubmed: 16980551
Can Respir J. 2018 Nov 22;2018:7260178
pubmed: 30595776
Lung. 2014 Feb;192(1):141-9
pubmed: 24221341
J Thorac Dis. 2019 Jun;11(6):2448-2457
pubmed: 31372282
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
N Engl J Med. 2006 Apr 20;354(16):1671-84
pubmed: 16625008
BMJ Open. 2013 Jul 31;3(7):
pubmed: 23903809
Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824
pubmed: 21471066
Ann Am Thorac Soc. 2017 Jun;14(6):844-850
pubmed: 28570160
J Inflamm (Lond). 2019 Jan 15;16:1
pubmed: 30675131
Am J Respir Crit Care Med. 2006 Oct 15;174(8):906-14
pubmed: 16858012
Medicine (Baltimore). 2018 Nov;97(45):e13087
pubmed: 30407312
Intern Med. 2017;56(6):621-626
pubmed: 28321059
Am J Respir Crit Care Med. 2015 Jul 15;192(2):e3-19
pubmed: 26177183
J Biol Chem. 2011 Dec 30;286(52):44326-35
pubmed: 22030390
Am J Respir Crit Care Med. 2013 Sep 15;188(6):733-48
pubmed: 24032382
JAMA. 1968 Jun 24;204(13):1193-5
pubmed: 5694700